IL87768A - Blood assay including erythrocyte agglutination and reagent for the assay comprising conjugate of erythrocyte binding molecule and analyte binding molecule - Google Patents

Blood assay including erythrocyte agglutination and reagent for the assay comprising conjugate of erythrocyte binding molecule and analyte binding molecule

Info

Publication number: IL87768A
Authority: IL; Israel
Prior art keywords: erythrocyte; analyte; reagent; antibody; binding molecule
Prior art date: 1987-09-17

Application number

IL8776888A

Other languages

English (en)

Original Assignee

Agen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-17

Filing date

1988-09-15

Publication date

1994-12-29

1988-01-13 Priority claimed from US07/143,343 external-priority patent/US4894347A/en

1988-09-15 Application filed by Agen Ltd filed Critical Agen Ltd

1994-12-29 Publication of IL87768A publication Critical patent/IL87768A/en

Links

210000003743 erythrocyte Anatomy 0.000 title claims abstract description 236
230000027455 binding Effects 0.000 title claims abstract description 223
239000012491 analyte Substances 0.000 title claims abstract description 172
239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 120
230000004520 agglutination Effects 0.000 title claims abstract description 88
238000003556 assay Methods 0.000 title claims abstract description 50
210000004369 blood Anatomy 0.000 title claims description 61
239000008280 blood Substances 0.000 title claims description 61
238000007818 agglutination assay Methods 0.000 claims abstract description 33
239000000523 sample Substances 0.000 claims description 67
108090000765 processed proteins & peptides Proteins 0.000 claims description 60
239000012634 fragment Substances 0.000 claims description 56
239000000427 antigen Substances 0.000 claims description 46
102000036639 antigens Human genes 0.000 claims description 42
108091007433 antigens Proteins 0.000 claims description 42
210000004027 cell Anatomy 0.000 claims description 29
238000012360 testing method Methods 0.000 claims description 25
102000028180 Glycophorins Human genes 0.000 claims description 22
108091005250 Glycophorins Proteins 0.000 claims description 22
102000004856 Lectins Human genes 0.000 claims description 21
108090001090 Lectins Proteins 0.000 claims description 21
239000002523 lectin Substances 0.000 claims description 21
210000003617 erythrocyte membrane Anatomy 0.000 claims description 19
238000001514 detection method Methods 0.000 claims description 17
238000010168 coupling process Methods 0.000 claims description 15
230000008878 coupling Effects 0.000 claims description 14
238000005859 coupling reaction Methods 0.000 claims description 14
108010036176 Melitten Proteins 0.000 claims description 12
230000009870 specific binding Effects 0.000 claims description 12
102000004169 proteins and genes Human genes 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 10
239000012528 membrane Substances 0.000 claims description 10
229940127121 immunoconjugate Drugs 0.000 claims description 9
230000002934 lysing effect Effects 0.000 claims description 9
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 6
102000003886 Glycoproteins Human genes 0.000 claims description 6
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 6
229960005156 digoxin Drugs 0.000 claims description 6
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 6
239000003154 D dimer Substances 0.000 claims description 5
108090000288 Glycoproteins Proteins 0.000 claims description 5
108010090054 Membrane Glycoproteins Proteins 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 5
108010052295 fibrin fragment D Proteins 0.000 claims description 5
229930186217 Glycolipid Natural products 0.000 claims description 4
102000012750 Membrane Glycoproteins Human genes 0.000 claims description 4
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
102000008102 Ankyrins Human genes 0.000 claims description 3
108010049777 Ankyrins Proteins 0.000 claims description 3
101001048057 Dictyostelium discoideum 32 kDa heat shock protein Proteins 0.000 claims description 3
102100038002 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Human genes 0.000 claims description 3
101710133440 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Proteins 0.000 claims description 3
241000002163 Mesapamea fractilinea Species 0.000 claims description 3
102000007327 Protamines Human genes 0.000 claims description 3
108010007568 Protamines Proteins 0.000 claims description 3
102000005890 Spectrin Human genes 0.000 claims description 3
108010019965 Spectrin Proteins 0.000 claims description 3
239000007822 coupling agent Substances 0.000 claims description 3
150000002339 glycosphingolipids Chemical class 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
238000011534 incubation Methods 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
229940048914 protamine Drugs 0.000 claims description 3
239000012088 reference solution Substances 0.000 claims description 3
108010085238 Actins Proteins 0.000 claims description 2
102000007469 Actins Human genes 0.000 claims description 2
108010052285 Membrane Proteins Proteins 0.000 claims description 2
230000009149 molecular binding Effects 0.000 claims description 2
VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 claims 6
101710160621 Fusion glycoprotein F0 Proteins 0.000 claims 1
102000018697 Membrane Proteins Human genes 0.000 claims 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 1
239000013074 reference sample Substances 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 10
239000000562 conjugate Substances 0.000 description 61
238000000034 method Methods 0.000 description 24
238000002360 preparation method Methods 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 15
238000003018 immunoassay Methods 0.000 description 15
241000725303 Human immunodeficiency virus Species 0.000 description 13
230000004523 agglutinating effect Effects 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
239000000470 constituent Substances 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000002245 particle Substances 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
238000004132 cross linking Methods 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
238000001641 gel filtration chromatography Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
102000057297 Pepsin A Human genes 0.000 description 5
108090000284 Pepsin A Proteins 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 5
229940111202 pepsin Drugs 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
238000000926 separation method Methods 0.000 description 5
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
101150004533 EBM gene Proteins 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000002372 labelling Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
-1 N-t-butyloxycarbonyl amino Chemical group 0.000 description 3
101100322033 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ABM1 gene Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000036436 anti-hiv Effects 0.000 description 3
210000003567 ascitic fluid Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
229960003067 cystine Drugs 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
239000011521 glass Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
239000004816 latex Substances 0.000 description 3
229920000126 latex Polymers 0.000 description 3
239000003446 ligand Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
238000001262 western blot Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101000896275 Homo sapiens Embigin Proteins 0.000 description 2
101710125418 Major capsid protein Proteins 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000007365 Sialoglycoproteins Human genes 0.000 description 2
108010032838 Sialoglycoproteins Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
230000000621 autoagglutination Effects 0.000 description 2
239000003659 bee venom Substances 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
238000009582 blood typing Methods 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000863 peptide conjugate Substances 0.000 description 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
238000012552 review Methods 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012956 testing procedure Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
150000003573 thiols Chemical group 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
239000003643 water by type Substances 0.000 description 2
XUDGDVPXDYGCTG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyloxyethylsulfonyl]ethyl carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCCS(=O)(=O)CCOC(=O)ON1C(=O)CCC1=O XUDGDVPXDYGCTG-UHFFFAOYSA-N 0.000 description 1
BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
GGBIMBICBVPVDL-UHFFFAOYSA-N 2-(propyldisulfanyl)pyridine Chemical group CCCSSC1=CC=CC=N1 GGBIMBICBVPVDL-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
WAPZQDVCJQYDTN-ZQIUZPCESA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-aminohexyl)-n-(2-iodoacetyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)N(C(=O)CI)CCCCCCN)SC[C@@H]21 WAPZQDVCJQYDTN-ZQIUZPCESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108091006515 Anion channels Proteins 0.000 description 1
102000037829 Anion channels Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
101710169873 Capsid protein G8P Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
101710156564 Major tail protein Gp23 Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
208000034809 Product contamination Diseases 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102100036422 Speckle-type POZ protein Human genes 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
244000166550 Strophanthus gratus Species 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical group N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
229960002694 emetine Drugs 0.000 description 1
AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000005182 global health Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
CYPPCCJJKNISFK-UHFFFAOYSA-J kaolinite Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[O-][Si](=O)O[Si]([O-])=O CYPPCCJJKNISFK-UHFFFAOYSA-J 0.000 description 1
229910052622 kaolinite Inorganic materials 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000010339 medical test Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000008520 organization Effects 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
229960003343 ouabain Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
108020001775 protein parts Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000005258 radioactive decay Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
102220188866 rs142192701 Human genes 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
229950009641 sparsomycin Drugs 0.000 description 1
XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IL8776888A 1987-09-17 1988-09-15 Blood assay including erythrocyte agglutination and reagent for the assay comprising conjugate of erythrocyte binding molecule and analyte binding molecule IL87768A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
AUPI440087		1987-09-17
US11131387A	1987-10-22	1987-10-22
AUPI501887		1987-10-22
US07/143,343 US4894347A (en)	1987-09-17	1988-01-13	Erythrocyte agglutination assay

Publications (1)

Publication Number	Publication Date
IL87768A true IL87768A (en)	1994-12-29

Family

ID=27424223

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8776888A IL87768A (en)	1987-09-17	1988-09-15	Blood assay including erythrocyte agglutination and reagent for the assay comprising conjugate of erythrocyte binding molecule and analyte binding molecule

Country Status (10)

Country	Link
EP (1)	EP0308242B1 (de)
JP (1)	JP2553159B2 (de)
AT (1)	ATE116740T1 (de)
DE (1)	DE3852683T2 (de)
DK (1)	DK519388A (de)
ES (1)	ES2070129T3 (de)
IL (1)	IL87768A (de)
NO (1)	NO175024C (de)
NZ (1)	NZ226202A (de)
OA (1)	OA08953A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5494800A (en) *	1987-01-29	1996-02-27	Cytosignet, Inc.	Analyte detection in particulate-containing samples
DE3822750A1 (de) *	1988-07-05	1990-01-11	Boehringer Mannheim Gmbh	Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
CU22737A1 (es) *	1997-04-28	2002-02-28	Ct Ingenieria Genetica Biotech	Proteínas de fusión recombinantes basadas en adhesinas bacterianas para el desarrollo de ensayos diagnóstico
EP2674757A3 (de)	2005-11-12	2014-03-05	Platform Diagnostics Limited	Agglutinierungstest
EP2603520A4 (de) *	2010-08-10	2014-02-19	Ecole Polytech	Erythrozytenbindende therapeutika
GB201403115D0 (en) *	2014-02-21	2014-04-09	Qbd Qs Ip Ltd	Red blood cell detection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4433059A (en) *	1981-09-08	1984-02-21	Ortho Diagnostic Systems Inc.	Double antibody conjugate
CA1194415A (en) *	1982-05-05	1985-10-01	E. I. Du Pont De Nemours And Company	Immunoglobulin half-molecules and process for producing hybrid antibodies
US4446233A (en) *	1982-05-05	1984-05-01	E. I. Du Pont De Nemours And Company	Homogeneous immunoassay using covalent hybrid antibodies
US4594327A (en) *	1983-11-02	1986-06-10	Syntex (U.S.A.) Inc.	Assay method for whole blood samples
DE3583278D1 (de) *	1984-04-23	1991-07-25	Boston Biomed Res Inst	Doppelspezifische antikoerper-determinanten.
WO1988003650A1 (en) *	1986-11-13	1988-05-19	Gene Labs, Inc.	Blood affinity diagnostic method

1988
- 1988-09-15 NZ NZ226202A patent/NZ226202A/en unknown
- 1988-09-15 IL IL8776888A patent/IL87768A/en active Protection Beyond IP Right Term
- 1988-09-15 OA OA59432A patent/OA08953A/xx unknown
- 1988-09-16 NO NO884131A patent/NO175024C/no unknown
- 1988-09-16 AT AT88308590T patent/ATE116740T1/de not_active IP Right Cessation
- 1988-09-16 DK DK519388A patent/DK519388A/da not_active Application Discontinuation
- 1988-09-16 DE DE3852683T patent/DE3852683T2/de not_active Expired - Lifetime
- 1988-09-16 ES ES88308590T patent/ES2070129T3/es not_active Expired - Lifetime
- 1988-09-16 EP EP88308590A patent/EP0308242B1/de not_active Expired - Lifetime
- 1988-09-17 JP JP63231517A patent/JP2553159B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2553159B2 (ja)	1996-11-13
NO884131L (no)	1989-03-20
OA08953A (fr)	1990-11-30
ATE116740T1 (de)	1995-01-15
NO175024B (no)	1994-05-09
EP0308242B1 (de)	1995-01-04
DK519388D0 (da)	1988-09-16
DE3852683D1 (de)	1995-02-16
ES2070129T3 (es)	1995-06-01
DE3852683T2 (de)	1995-05-11
NO175024C (no)	1994-08-17
JPH01153960A (ja)	1989-06-16
NO884131D0 (no)	1988-09-16
EP0308242A2 (de)	1989-03-22
DK519388A (da)	1989-03-18
NZ226202A (en)	1992-01-29
EP0308242A3 (en)	1990-10-10

Legal Events

Date	Code	Title
1999-04-11	KB	Patent renewed
2002-11-10	KB	Patent renewed
2006-10-30	KB	Patent renewed
2009-05-03	EXTN	Extension order renewed

Publication	Publication Date	Title
US5086002A (en)	1992-02-04	Erythrocyte agglutination assay
US4894347A (en)	1990-01-16	Erythrocyte agglutination assay
US4935343A (en)	1990-06-19	Monoclonal antibodies for interleukin-1β
EP0166623A2 (de)	1986-01-02	Antikörper-Lectin-Sandwichtest
JP2636331B2 (ja)	1997-07-30	抗原特異的な抗体の一段階測定法およびそれに適する試薬
US4929543A (en)	1990-05-29	Process for the determination of an antibody in human body fluids
JP3499570B2 (ja)	2004-02-23	Ｔｓｈレセプター自己抗体を検出するためのレセプター結合アッセイ
AU2011330997A1 (en)	2013-06-13	Device and method for immunotrials
CA1148858A (en)	1983-06-28	Determination of immunoglobulins
US5583003A (en)	1996-12-10	Agglutination assay
EP0308242B1 (de)	1995-01-04	Agglutinationstest
AP156A (en)	1991-11-06	Agglutination assay.
EP0448632A1 (de)	1991-10-02	Anti-idiotopisches immunometrisches bestimmungsverfahren
US5856106A (en)	1999-01-05	Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US6210906B1 (en)	2001-04-03	Specific antibodies to kringle 5 of apo(a) and methods of use therefor
AP81A (en)	1990-04-28	Agglutination assay
AU624580B2 (en)	1992-06-18	Reagent, method and kit for agglutination assay
IE882828L (en)	1989-03-17	Agglutination assay
WO1997008549A1 (fr)	1997-03-06	Procede de detection d'affections renales, produit et kit de diagnostic appropries
KR940008091B1 (ko)	1994-09-02	리간드의 면역학적 검출방법
AU633633B2 (en)	1993-02-04	Agglutination assay
JPH04134097A (ja)	1992-05-07	ラミニン　フラグメント
JP2004184125A (ja)	2004-07-02	免疫学的検出試薬、該試薬を用いた検出方法及び該試薬の製造方法
JPH0342572A (ja)	1991-02-22	ラミニン測定試薬
JPH02264863A (ja)	1990-10-29	ヒトイムノグロブリンＦｃ断片と人以外の哺乳動物抗体とのコンジユゲート